Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating restated by equities researchers at Oppenheimer in a report released on Tuesday. They currently have a $55.00 price objective on the stock. Oppenheimer’s price target would suggest a potential upside of 7.84% from the stock’s current price.

Several other research analysts have also commented on the stock. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. Craig Hallum restated a “buy” rating and issued a $62.00 price target (up previously from $52.00) on shares of Omnicell in a report on Monday, October 30th. Cantor Fitzgerald raised their price target on shares of Omnicell to $58.00 and gave the company an “overweight” rating in a report on Friday, October 27th. Finally, Benchmark raised their price target on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $55.14.

Shares of Omnicell (OMCL) traded down $1.15 during mid-day trading on Tuesday, hitting $51.00. 229,600 shares of the stock traded hands, compared to its average volume of 256,245. Omnicell has a 1-year low of $31.85 and a 1-year high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. The business had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 EPS. analysts forecast that Omnicell will post 0.12 earnings per share for the current fiscal year.

In other Omnicell news, EVP Dan S. Johnston sold 14,613 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.81, for a total value of $698,647.53. Following the completion of the sale, the executive vice president now owns 43,621 shares of the company’s stock, valued at $2,085,520.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter J. Kuipers sold 4,724 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the sale, the vice president now directly owns 40,544 shares of the company’s stock, valued at approximately $1,935,570.56. The disclosure for this sale can be found here. Insiders sold 38,944 shares of company stock worth $1,889,592 in the last 90 days. 3.77% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in OMCL. Janus Henderson Group PLC grew its position in shares of Omnicell by 129.6% during the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after buying an additional 695,334 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Omnicell by 124.9% during the second quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock worth $28,481,000 after buying an additional 367,019 shares in the last quarter. First Light Asset Management LLC grew its position in shares of Omnicell by 108.0% during the second quarter. First Light Asset Management LLC now owns 278,294 shares of the company’s stock worth $11,994,000 after buying an additional 144,471 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Omnicell by 70.2% during the second quarter. Russell Investments Group Ltd. now owns 347,914 shares of the company’s stock worth $14,995,000 after buying an additional 143,474 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its position in shares of Omnicell by 47.1% during the second quarter. Rice Hall James & Associates LLC now owns 434,422 shares of the company’s stock worth $18,724,000 after buying an additional 139,069 shares in the last quarter. 99.84% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/06/omnicell-omcl-rating-reiterated-by-oppenheimer.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.